Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 510408, 8 pages
http://dx.doi.org/10.1155/2014/510408
Research Article

Establishment of Cell Lines from Both Myeloma Bone Marrow and Plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a Single Patient

1Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-Ku, Seoul 110-744, Republic of Korea
2Cancer Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-Ku, Seoul 110-799, Republic of Korea
3Functional Genome Institute, PDXen Biosystem Inc., 437 Dongil-ro, Kwangjin-Ku, Seoul 143-901, Republic of Korea

Received 15 April 2014; Accepted 30 June 2014; Published 12 August 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Youngil Koh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Podar, D. Chauhan, and K. C. Anderson, “Bone marrow microenvironment and the identification of new targets for myeloma therapy,” Leukemia, vol. 23, no. 1, pp. 10–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Dimopoulos and E. Terpos, “Multiple myeloma,” Annals of Oncology, vol. 21, no. 7, pp. vii143–vii150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Mahindra, T. Hideshima, and K. C. Anderson, “Multiple myeloma: biology of the disease,” Blood Reviews, vol. 24, supplement 1, pp. S5–S11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Moreau, P. G. Richardson, M. Cavo et al., “Proteasome inhibitors in multiple myeloma: 10 years later,” Blood, vol. 120, no. 5, pp. 947–959, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Larocca and A. Palumbo, “Evolving paradigms in the treatment of newly diagnosed multiple myeloma,” JNCCN: Journal of the National Comprehensive Cancer Network, vol. 9, no. 10, pp. 1186–1196, 2011. View at Google Scholar · View at Scopus
  6. K. Bink, E. Haralambieva, M. Kremer et al., “Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics,” Haematologica, vol. 93, no. 4, pp. 623–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Dimopoulos, J. Goldstein, L. Fuller, K. Delasalle, and R. Alexanian, “Curability of solitary bone plasmacytoma,” Journal of Clinical Oncology, vol. 10, no. 4, pp. 587–590, 1992. View at Google Scholar · View at Scopus
  8. P. Galieni, M. Cavo, A. Pulsoni et al., “Clinical outcome of extramedullary plasmacytoma,” Haematologica, vol. 85, no. 1, pp. 47–51, 2000. View at Google Scholar · View at Scopus
  9. C. Alexiou, R. J. Kau, H. Dietzfelbinger et al., “Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts,” Cancer, vol. 85, no. 11, pp. 2305–2314, 1999. View at Google Scholar
  10. R. Jyothirmayi, V. P. Gangadharan, M. K. Nair, and B. Rajan, “Radiotherapy in the treatment of solitary plasmacytoma,” British Journal of Radiology, vol. 70, pp. 511–516, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Bladé, C. Fernández de Larrea, L. Rosiñol, M. T. Cibeira, R. Jiménez, and R. Powles, “Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach,” Journal of Clinical Oncology, vol. 29, no. 28, pp. 3805–3812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. L. G. Shaffer, M. L. Slovak, and L. J. Campbell, “International Standing Committee on Human Cytogenetic Nomenclature,” in Proceedings of the International System for Human Cytogenetic Nomenclature, Basel, Switzerland, 2009.
  13. A. I. C. C. Baba, Comparative Oncology, The Publishing House of the Romanian Academy, Bucharest, Romania, 2007.
  14. V. M. Lauta, “A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications,” Cancer, vol. 97, no. 10, pp. 2440–2452, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. U. H. Weidle, S. Klostermann, D. Eggle, and A. Krüger, “Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer,” Cancer Genomics and Proteomics, vol. 7, no. 6, pp. 287–302, 2010. View at Google Scholar · View at Scopus
  16. H. G. Drexler and Y. Matsuo, “Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia,” Leukemia Research, vol. 24, no. 8, pp. 681–703, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Yuan, R. Shah, A. Kulharya, and C. Ustun, “Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient,” Leukemia Research, vol. 34, no. 7, pp. 954–957, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Balsas, P. Galán-Malo, I. Marzo, and J. Naval, “Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy,” Leukemia Research, vol. 36, no. 2, pp. 212–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Nilsson, M. Höglund, S. Lenhoff et al., “A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences,” British Journal of Haematology, vol. 120, no. 6, pp. 960–969, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Koren-Michowitz, I. Hardan, J. Berghoff et al., “Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis,” Cancer Letters, vol. 255, no. 2, pp. 307–314, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. K. Stewart and R. Fonseca, “Prognostic and therapeutic significance of myeloma genetics and gene expression profiling,” Journal of Clinical Oncology, vol. 23, no. 26, pp. 6339–6344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Bommert, R. C. Bargou, and T. Stühmer, “Signalling and survival pathways in multiple myeloma,” European Journal of Cancer, vol. 42, no. 11, pp. 1574–1580, 2006. View at Publisher · View at Google Scholar · View at Scopus